Daiichi Signs an Exclusive License Agreement with Esperion, for $1.2B

 Daiichi Signs an Exclusive License Agreement with Esperion, for $1.2B

Daiichi Signs an Exclusive License Agreement with Esperion, for $1.2B

Shots:
  • Esperion to receive $150M upfront, $150M sales milestones and up to $900M regulatory
    milestones including royalties. Daiichi to get exclusive commercialization rights for Esperion’s bempedoic acid and bempedoic acid /ezetimibe drug in EU and Switzerland
  • Esperion plans for the file NDA and MAA for bempedoic acid / ezetimibe to the US FDA and
    EMA in Q1’19 & Q2’19 respectively, with its expected results in H1’19
  • Bempedoic Acid is a once daily ATP Citrate Lyase inhibitor, indicated for the reduction of LDL-C by activating LDL receptor

Click here to read full press release/ article | Ref: Esperion | Image: Investors

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post